UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2018

Commission File Number: 001-36582

Auris Medical Holding AG

(Exact name of registrant as specified in its charter)

Bahnhofstrasse 21
6300 Zug, Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes _____ No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes _____ No X

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number 333-223855) of Auris Medical Holding AG and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit 99.3 to this Report on Form 6-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Auris Medical Holding AG

By: /s/ Hernan Levett
Name: Hernan Levett
Title: Chief Financial Officer

Date: May 15, 2018

EXHIBIT INDEX

Exhibit Number	Description
99.1	Unaudited Condensed Consolidated Interim Financial Statements
99.2	Management's Discussion and Analysis of Financial Condition and Results of Operations
99.3	Press Release dated May 15, 2018

Exhibit 99.1

Unaudited Condensed Consolidated Interim Financial Statements as of March 31, 2018 and December 31, 2017 and for the Three Months Ended March 31, 2018 and 2017

Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Loss
Condensed Consolidated Interim Statement of Financial Position
Condensed Consolidated Interim Statement of Changes in Equity
Condensed Consolidated Interim Statement of Cash Flows
Notes to the Condensed Consolidated Interim Financial Statements

Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Loss (unaudited)
For the Three Months Ended March 31, 2018 and 2017 (in CHF)

	Note	THREE MONTHS ENDED MARCH 31 2018	2017
Research and development		(2,943,221)	(5,981,419)
General and administrative		(1,360,714)	(1,425,491)
Operating loss		**(4,303,935)**	**(7,406,910)**
Interest income		—	31,297
Interest expense	4	(348,927)	(421,435)
Foreign currency exchange loss, net		(88,290)	(338,160)
Revaluation gain from derivative financial instruments	4,5	3,300,696	233,123
Transaction costs	5	(313,760)	(506,234)
Loss before tax		**(1,754,216)**	**(8,408,319)**
Income tax gain	3	8,726	8,191
Net loss attributable to owners of the Company		**(1,745,490)**	**(8,400,128)**
Other comprehensive loss:			
Items that will never be reclassified to profit or loss			
Remeasurement of defined benefit liability, net of taxes of CHF 0.00		280,801	227,827
Items that are or may be reclassified to profit or loss			
Foreign currency translation differences, net of taxes of CHF 0.00		15,135	19,925
Other comprehensive income, net of taxes of CHF 0		**295,936**	**247,752**
Total comprehensive loss attributable to owners of the Company		**(1,449,554)**	**(8,152,376)**
Basic and diluted loss per share	8	(0.30)	(2.15)

The accompanying notes form an integral part of these condensed consolidated interim financial statements

Condensed Consolidated Interim Statement of Financial Position (unaudited)
As of March 31, 2018 and December 31, 2017 (in CHF)

	Note	MARCH 31, 2018	DECEMBER 31, 2017
ASSETS			
Non-current assets			
Property and equipment		229,450	252,899
Intangible assets		1,629,100	1,629,100
Other non-current financial assets		76,710	76,710
Total non-current assets		**1,935,260**	**1,958,709**
Current assets			
Other receivables		370,001	241,281
Prepayments		832,033	652,913
Cash and cash equivalents		12,653,690	14,973,369
Total current assets		**13,855,724**	**15,867,563**
Total assets		**15,790,984**	**17,826,272**
EQUITY AND LIABILITIES			
Equity			
Share capital	5	122,348	19,349,556
Share premium		136,332,888	114,648,228
Foreign currency translation reserve		(17,912)	(33,047)
Accumulated deficit		(137,850,994)	(136,126,946)
Total shareholders' deficit attributable to owners of the Company		**(1,413,670)**	**(2,162,209)**
Non-current liabilities			
Loan	4	4,414,950	5,584,297
Derivative financial instruments	4,5	1,019,813	1,836,763
Employee benefits		1,734,689	1,962,970
Deferred tax liabilities	3	170,083	178,809
Total non-current liabilities		**7,339,535**	**9,562,839**
Current liabilities			
Loan	4	4,226,770	4,542,109
Trade and other payables		1,355,721	1,200,820
Accrued expenses		4,282,628	4,682,713
Total current liabilities		**9,865,119**	**10,425,642**
Total liabilities		**17,204,654**	**19,988,481**
Total equity and liabilities		**15,790,984**	**17,826,272**

The accompanying notes form an integral part of these condensed consolidated interim financial statements

Condensed Consolidated Interim Statement of Changes in Equity (unaudited)
As of March 31, 2018 and 2017 (in CHF)

		ATTRIBUTABLE TO OWNERS OF THE COMPANY				
	NOTE	SHARE CAPITAL	SHARE PREMIUM	FX TRANSLATION RESERVE	ACCUMULATED DEFICIT	TOTAL EQUITY / (DEFICIT)
As of January 1, 2017		**13,731,881**	**112,838,815**	**(83,544)**	**(112,344,303)**	**14,142,849**
Total comprehensive loss						
Net loss		—	—	—	(8,400,128)	**(8,400,128)**
Other comprehensive income		—	—	19,925	227,827	**247,752**
Total comprehensive income/(loss)		—	—	**19,925**	**(8,172,301)**	**(8,152,376)**
Transactions with owners of the Company						
Transaction costs		—	(397,685)	—	—	**(397,685)**
Share based payments	7	—	—	—	53,900	**53,900**
Capital increase		4,000,000	907,841	—	—	**4,907,841**
Balance at March 31, 2017	**5**	**17,731,881**	**113,348,971**	**(63,619)**	**(120,462,704)**	**10,554,529**
As of January 1, 2018		**19,349,556**	**114,648,228**	**(33,047)**	**(136,126,946)**	**(2,162,209)**
Total comprehensive loss						
Net loss		—	—	—	(1,745,490)	**(1,745,490)**
Other comprehensive income		—	—	15,135	280,801	**295,936**
Total comprehensive income/(loss)		—	—	**15,135**	**(1,464,689)**	**(1,449,554)**
Transactions with owners of the Company						
Reorganization of group structure	5	(24,347,208)	24,347,208	—	—	**—**
Transaction costs	5	—	(341,226)	—	—	**(341,226)**
Share based payments	7	—	—	—	(259,359)	**(259,359)**
Capital increase	5	5,120,000	(2,321,322)	—	—	**2,798,678**
Balance at March 31, 2018	**5**	**122,348**	**136,332,888**	**(17,912)**	**(137,850,994)**	**(1,413,670)**

The accompanying notes form an integral part of these condensed consolidated interim financial statements

Condensed Consolidated Interim Statement of Cash Flows (unaudited)
For the Three Months Ended March 31, 2018 and 2017 (in CHF)

	Note	THREE MONTHS ENDED MARCH 31, 2018	THREE MONTHS ENDED MARCH 31, 2017
Cash flows from operating activities			
Net loss		**(1,745,490)**	**(8,400,128)**
Adjustments for:			
Depreciation		23,448	32,943
Unrealized foreign currency exchange loss, net		155,928	362,564
Net interest expense/(income)		340,549	383,263
Share based payments	7	(259,359)	53,900
Transaction costs		313,760	506,234
Employee benefits		52,520	30,502
Revaluation gain on derivative financial instruments		(3,300,696)	(233,121)
Income tax gain	3	(8,726)	(8,191)
		(4,428,066)	**(7,272,034)**
Changes in:			
Other receivables		(128,720)	(36,844)
Prepayments		(179,120)	75,315
Trade and other payables		154,901	256,391
Accrued expenses		(400,085)	201,994
Net cash used in operating activities		**(4,981,090)**	**(6,775,178)**
Cash flows from investing activities			
Purchase of property and equipment		—	(74,303)
Interest received		—	29,943
Net cash used in investing activities		**—**	**(44,360)**
Cash flows from financing activities			
Proceeds from public offering	5	5,282,425	9,321,807
Transaction costs		(654,986)	(227,422)
Repayment of loan	4	(1,426,393)	—
Interest paid		(237,891)	(307,452)
Net cash from financing activities		**2,963,155**	**8,786,933**
Net (decrease)/increase in cash and cash equivalents		**(2,017,935)**	**1,967,395**
Cash and cash equivalents at beginning of the period		14,973,369	32,442,222
Net effect of currency translation on cash		(301,744)	(563,092)
Cash and cash equivalents at end of the period		**12,653,690**	**33,846,525**

The accompanying notes form an integral part of these condensed consolidated interim financial statements

AURIS MEDICAL HOLDING AG
Notes to the Condensed Consolidated Interim Financial Statements
as of March 31, 2018 and December 31, 2017 and for the Three Months Ended March 31, 2018 and 2017 (in CHF)

1. Reporting entity

Auris Medical Holding AG, previously named Auris NewCo Holding AG, (the "Company" or "Auris NewCo") is a corporation (Aktiengesellschaft) organized in accordance with Swiss law and domiciled in Switzerland and was established on March 13, 2018. On March 13, 2018, the Auris NewCo Holding AG merged (the "Merger") with Auris Medical Holding AG ("Auris OldCo"), a corporation (Aktiengesellschaft) organized in accordance with Swiss law and domiciled in Switzerland. The Merger took place following Auris OldCo shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Auris NewCo Holding AG changed its name to Auris Medical Holding AG following consummation of the Merger. Following the Merger, the Company had a share capital of CHF 122,347.76, divided into 6,117,388 common shares with a nominal value of CHF 0.02 each. Pursuant to the Merger, the Auris OldCo's shareholders received one common share with a nominal value of CHF 0.02 of the Company for every 10 of our common shares held prior to the Merger, effectively resulting in a "reverse stock split" at a ratio of 10-for-1. On March 14, 2018 the common shares of Auris NewCo began trading on the Nasdaq Capital Market under the trading symbol "EARS".

The Company's registered address is Bahnhofstrasse 21, 6300 Zug. These condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the "Group" and individually as "Group entities"). These condensed consolidated interim financial statements also include financial information of Auris OldCo prior to the Merger as discussed below. The Company is the ultimate parent of the following Group entities:

- Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000
- Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000
- Auris Medical Inc., Chicago, United States (100%) with a nominal share capital of USD 15,000
- Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

The Group is primarily involved in the development of pharmaceutical products for the treatment of neurotologic disorders, in particular tinnitus, hearing loss and vertigo. Its most advanced projects are in the late stage of clinical development.

2. Basis of preparation

Statement of compliance

These condensed consolidated interim financial statements as of March 31, 2018 and December 31, 2017 and for the three months ended March 31, 2018 have been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting* ("IAS 34") and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2017.

These condensed consolidated interim financial statements include all adjustments that are necessary to fairly state the results of the interim period. The Group believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. Management does not consider the business to be seasonal or cyclical.

Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board, have been condensed or omitted as permitted by IAS 34. The condensed consolidated statement of financial position as of December 31, 2017 was derived from the audited consolidated financial statements.

The interim condensed consolidated financial statements were authorized for issuance by the Company's Audit Committee on May 11, 2018.

Functional and reporting currency

These interim condensed consolidated financial statements are presented in Swiss Francs ("CHF"), which is the Company's functional currency ("functional currency") and the Group's reporting currency.

Considering reorganization / Merger

The Merger is not a business combination and is accounted for as a reorganization. Therefore, the condensed consolidated interim financial statements of the Company are a continuation of the financial information of Auris OldCo except that the condensed consolidated interim financial statements reflect a reclassification between share capital and share premium in order to reflect the share capital of Auris NewCo. For the periods prior to the Merger, in calculating loss per share, the weighted average number of shares outstanding is calculated based on the number of weighted average shares issued by Auris OldCo, adjusted for the reverse stock split ratio of 10-for-1.

Related Party Transaction

On February 9, 2018, Thomas Meyer, our Chief Executive Officer, entered into a shares transfer agreement with the Company to facilitate the rounding up of fractional shares resulting from the exchange ratio used in the Merger. Pursuant to the terms of the share transfer agreement, Mr. Meyer has committed to transfer, at no consideration, a common share to any shareholder entitled to a fraction of a common share as part of the Merger. Pursuant to the share transfer agreement, neither the Company nor Mr. Meyer will receive any compensation for this arrangement. Any expenses incurred by Mr. Meyer in connection with the transfers under such agreement were borne by the Company.

Significant accounting policies

The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its audited consolidated financial statements as of and for the year ended December 31, 2017 and have been applied consistently to all periods presented in these condensed consolidated interim financial statements, unless otherwise indicated.

New standards, amendments and interpretations adopted by the Group

The Group has not early adopted any standard, interpretation or amendment that was issued, but is not yet effective.

A number of new standards, amendments to standards and interpretations are effective for the Group's 2018 reporting year. The application of these new standards, amendments to standards and interpretations does not have material impact on the financial statements of the Group.

3. Taxation

The Group's income tax expense recognized in the condensed interim consolidated statement of profit or loss is presented as follows:

	THREE MONTHS ENDED	
	March 31, 2018	**March 31, 2017**
Deferred income tax expense	—	—
Deferred income tax gain	8,726	8,191
Total income tax income	**8,726**	**8,191**

The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of March 31, 2018 and 2017 is presented as follows:

	March 31, 2018	**March 31, 2017**
Deferred Tax liabilities		
Intangible assets	(349,052)	(338,493)
Hercules Loan & Warrant	(40,643)	(70,400)
Total	**(389,695)**	**(408,893)**
Deferred Tax assets		
Net operating loss (NOL)	219,612	220,502
Total	**219,612**	**220,502**
Deferred Tax, net	**(170,083)**	**(188,391)**

4. Loan and Warrant

On July 19, 2016 the Company entered into a Loan and Security Agreement (the "Hercules Loan and Security Agreement") for a secured term loan facility of up to US$20.0 million with Hercules Capital, Inc. as administrative agent ("Hercules") and the lenders party thereto. An initial tranche of US$12.5 million was drawn on July 19, 2016, concurrently with the execution of the Hercules Loan and Security Agreement. The loan matures on January 2, 2020 and bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. The loan is secured by a pledge of the shares of Auris Medical AG owned by the Company, all intercompany receivables owed to the Company by its Swiss subsidiaries and a security assignment of the Company's bank accounts.

On April 5, 2018 the Company entered into an agreement with Hercules whereby the terms of the Company's Loan and Security Agreement with Hercules were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Loan and Security Agreement.

The loan was initially recognized at transaction value with deductions of the fair value of the warrant at transaction date and directly attributable transactions costs.

Subsequent to initial recognition, the loan is measured at amortized cost using the effective interest method. Applying this method, the calculated value of the loan as of March 31, 2018 is CHF 8,641,720. Of the CHF 8,641,720 amortization payments due within the next 12 months in an amount of CHF 4,226,770 are reclassified as current liabilities.

In connection with the loan facility, the Company issued Hercules a warrant to purchase up to 241,117 of its common shares at an exercise price of US$3.94 per share. As of March 13, 2018, following consummation of the Merger, the warrant is exercisable for 15,673 common shares at an exercise price of $39.40 per common share. Upon Hercules making the second advance under the loan facility, the warrant shall become exercisable for the additional 8,440 common shares (assuming the Company rounds up fractional common shares to the next whole common share). The warrant expires on July 19, 2023. The fair value calculation of the warrant is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk free rate in order to determine the fair value of the warrant. As the warrant is part of the loan transaction, its fair value was deducted from the loan proceeds and accounted for separately as non-current financial liability. Following the initial recognition, the warrant is measured at fair value and the changes in fair value are shown as profit or loss.

On March 31, 2018, the fair value of the warrant amounted to CHF 4,596. Therefore, the fair value decreased by the total amount of CHF 18,754 in the current year, resulting in a gain in the corresponding amount (fair value as of December 31, 2017: CHF 23,350).

5. Capital and reserves

Share capital

The issued share capital of the Company consisted of:

	Number of Common Shares	
	2018	**2017**
As of January 1	48,373,890	34,329,704
Common shares issued for capital increase	12,800,000	10,000,000
Adjustments during the Merger:		
- Issuance of Auris NewCo Shares	6,117,388	-
- Cancellation of Auris OldCo Shares	(61,173,890)	-
Shares outstanding after Merger on March 13 2018	6,117,388	-
Total, as of March 31	**6,117,388**	**44,329,704**

Shares have a nominal value of CHF 0.02 after the Merger and CHF 0.40 before the Merger, and all shares are fully paid in. As of March 31, 2018, the nominal value of the 6,117,388 issued shares amounted to CHF 122,347.76 (as of March 31, 2017, the nominal value of 44,329,704 issued shares amounted to CHF 17,731,881.60).

As of March 13, 2018, following consummation of the Merger, the number of shares were reduced by the ratio of 10 to 1 (effectively resulting in a "reverse share split") and the nominal value per share was reduced from CHF 0.40 to CHF 0.02. This resulted in a reclassification between share capital and share premium, totaling CHF 24,347,208, presented in the statement of changes in equity in the line reorganization of group structure.

Equity Offerings

On January 30, 2018, we completed a public offering of 12,499,999 common shares with a nominal value of CHF 0.40 each and concurrent offering of 7,499,999 warrants, each warrant entitling its holder to purchase one common share (the "January 2018 Registered Offering"). The net proceeds to the Company from the January 2018 Registered Offering were approximately $4.9 million, after deducting placement agent fees and other estimated offering expenses payable by the Company. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issued in the January 2018 Registered Offering were exercisable for up to 750,002 common shares (assuming the Company rounds up fractional common shares to the next whole common share) at an exercise price of $5.00 per common share.

As of March 31, 2018 the fair value of the warrants amounted to CHF 715,206. Since its initial recognition, the fair value of the warrants has decreased by CHF 1,768,541, resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).

On October 10, 2017 we entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC. Pursuant to the purchase agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares over the 30-month term of the purchase agreement. On January 23, 2018, we issued 300,000 of our common shares to LCP for an aggregate amount of CHF 136,077 under the purchase agreement.

The Company had transaction costs amounting to CHF 654,985. The transactions costs were recorded as CHF 341,226 in equity for the issuance of the common shares and CHF 313,760 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.

On February 21, 2017, in connection with a public offering of 12,499,000 common shares, the Company issued 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share at an exercise price of US$ 1.20. Additionally, the underwriter was granted a 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants, of which the underwriter partially exercised its option for 1,350,000 warrants. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issuable in the 2017 offering were exercisable for an aggregate of 794,000 common shares, at an exercise price of $12.00 per common share. As of March 31, 2018 the fair value of the warrants amounted to CHF 300,011. Therefore, the fair value decreased by the total amount of CHF 1,513,402 in the current year, resulting in a gain in the corresponding amount (fair value as of December 31, 2017: CHF 1,813,413).

Issue of common shares upon exercise of options

During the three months ended March 31, 2018, no options were exercised.

Controlled Equity Offering

On June 1, 2016, we entered into a Controlled Equity Offering Sales Agreement with Cantor, pursuant to which we might have offered and sold from time to time common shares, with a nominal value of CHF 0.40 per share, having an aggregate offering price of up to $35 million through Cantor. In the first quarter of 2018, we did not offer or sell any common shares under the Controlled Equity Offering Sales Agreement. The Controlled Equity Offering program terminated upon consummation of the Merger on March 13, 2018.

6. Employee benefits

	THREE MONTHS ENDED	
	MARCH 31, 2018	**MARCH 31, 2017**
Salaries	803,796	1,063,009
Pension costs	100,505	92,410
Share based compensation expense/(gain)	(259,359)	53,900
Other employee costs and social benefits	104,424	174,165
Total employee benefits	**749,366**	**1,383,483**

7. Share based payments

Share based compensation gain of CHF 259,359 was recognized for the three months ended March 31, 2018 due to the forfeiture of options related to the reduction in headcount (for the three months ended March 31, 2017: CHF 53,900).

No options were granted in the three months ended March 31, 2018.

8. Loss per share

	Three months ended March 31,	
	2018	**2017**
Loss attributable to owners of the Company	(1,745,490)	(8,400,128)
Weighted average number of shares outstanding	5,742,978	3,904,881
Basic and diluted loss per share	**(0.30)**	**(2.15)***

*The basic and diluted loss per share for the three months ended March 31, 2017 is revised to reflect the reverse-split ratio of 10 to 1 following the Merger on March 13, 2018.

For the three months ended March 31, 2018 and March 31, 2017 basic and diluted loss per share are calculated based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the stock option plans, as they would be anti-dilutive. As of the date hereof, the Company had 151,057 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2018 and March 31, 2018 was 217,582 (98,756 for the period between January 1, 2017 and March 31, 2017).

9. Events after the Reporting Period

Early Repayment under the Hercules Loan and Security Agreement

On April 5, 2018, the Company entered into an agreement with Hercules whereby the terms of the Company's Loan and Security Agreement with Hercules were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Loan and Security Agreement. The repayment of $5 million of the principal amount was executed on April 6, 2018.

Asset Purchase

On April 24, 2018, one of our subsidiaries entered into an agreement to purchase patents related to compositions for weight management and methods of reducing weight gain associated with olanzapine treatment.

Equity Commitment Purchase Agreement and Registration Rights Agreement

On May 2, 2018, the Company entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”). Pursuant to the Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Commitment Purchase Agreement.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited condensed consolidated interim financial statements as of and for the three months ended March 31, 2018 and 2017 included as Exhibit 99.1 to this Report on Form 6-K, which have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting*. We also recommend that you read our management's discussion and analysis and our audited consolidated financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2017 (the "Annual Report") filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to the U.S. Securities and Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, all references to "Auris Medical Holding AG" or "Auris," the "Company," "we," "our," "ours," "us" or similar terms refer to Auris Medical Holding AG, together with its subsidiaries, prior to our corporate reorganization by way of the Merger (as defined below) on March 13, 2018 (i.e. to the transferring entity), and to Auris Medical Holding AG (formerly Auris Medical NewCo Holding AG), together with its subsidiaries after the Merger (i.e. to the surviving entity). The trademarks, trade names and service marks appearing in this discussion and analysis are property of their respective owners.

Unless indicated or the context otherwise requires, all references in this Report on Form 6-K to our common shares as of any date prior to March 13, 2018 refer to our common shares (having a nominal value of CHF 0.40 each) prior to the 10:1 "reverse stock split" effected through the Merger and all references to our common shares as of, and after, March 13, 2018 refer to our common shares (having a nominal value of CHF 0.02 each) after the 10:1 "reverse stock split" effected through the Merger.

We prepare and report our consolidated financial statements and financial information in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (the "IASB"). None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). We maintain our books and records in Swiss Francs. We have made rounding adjustments to some of the figures included in this management's discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them. Unless otherwise indicated, all references to currency amounts in this discussion and analysis are in Swiss Francs.

This discussion and analysis is dated as of May 15, 2018.

Overview

We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. We have two lead clinical-stage product candidates, (i) Keyzilen® (AM-101), which is being developed for the treatment of acute inner ear tinnitus and (ii) AM-111, which is being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and fast track designation by the FDA. AM-125 is being developed for the treatment of vertigo. In addition, we are pursuing early stage projects for the treatment of tinnitus.

Recent Developments

TACTT3 Trial

On March 13, 2018 we announced that preliminary top-line data from the TACTT3 trial indicate that the study did not meet its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Index score from baseline to Day 84 in the active treated group compared to placebo either in the overall population or in the otitis media subpopulation. The Company is investigating the outcomes, including those in the previously conducted sister trial TACTT2.

HEALOS Trial Results

On November 28, 2017 we announced that the HEALOS Phase 3 clinical trial that investigated AM-111 in the treatment of acute inner ear hearing loss did not meet the primary efficacy endpoint of a statistically significant improvement in hearing from baseline to Day 28 compared to placebo for either active treatment groups in the overall study population. However, a post-hoc analysis of the subpopulation with profound acute hearing loss revealed a clinically meaningful and nominally significant improvement in the AM-111 0.4 mg/mL treatment group. At the same time we announced the early termination of the ASSENT Phase 3 trial as it was very similar in design to the HEALOS trial and, based on the new findings, was no longer adequate for testing AM-111.

On January 4, 2018 we announced that further analyses on the basis of the HEALOS full data set provided additional confirmation of and support for AM-111's otoprotective effects in the profound acute hearing loss subpopulation. Patients treated with AM-111 0.4 mg/mL showed a statistically significantly lower incidence of no hearing improvement (defined as less than 15 dB) compared to placebo by Day 91 (11.4 vs. 38.2%, risk ratio 0.30, p=0.012). They also had a lower incidence of no marked hearing improvement (defined as less than 30 dB) (28.6 vs. 50.0%, risk ratio 0.57, p=0.087). In addition, the significant improvement in pure tone hearing in the AM-111 0.4 mg/mL group was coupled with superior improvement in speech discrimination as the score of correctly recognized words improved by 49.2 percentage points to Day 91 compared to 30.4 percentage points in the placebo group (p=0.062).

We have shared the outcomes from the HEALOS trial with the European Medicines Agency (EMA) as part of a Protocol Assistance procedure with the EMA's Scientific Advice Working Party. In early May 2018 we received the EMA's feedback on the proposed design for a future Phase 3 trial with AM-111 mg/mL to support a marketing authorization as well on the regulatory path forward. The EMA reviewed the Company's proposed concept for a single pivotal trial with AM-111 0.4 mg/mL in patients suffering from acute profound hearing loss, which builds to a large extent on the design and outcomes from HEALOS. The Agency endorsed the proposed trial design, choice of efficacy and safety endpoints, as well as the statistical methodology. In addition, the EMA provided important guidance on the regulatory path forward and the maintenance of AM-111's orphan drug designation. We intend to seek in a next step also the FDA's advice through a Type C meeting.

Nasdaq Listing Requirements and Merger

The quantitative listing standards of the Nasdaq Capital Market require, among other things, that listed companies maintain a minimum closing bid price of $1.00 per share. To address our non-compliance with the minimum closing bid price requirement, on March 13, 2018 Auris Medical Holding AG merged into Auris Medical NewCo Holding AG (the "Merger"), a newly incorporated, wholly-owned Swiss subsidiary ("Auris NewCo") following shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Following the Merger, Auris NewCo, the surviving company had a share capital of CHF 122,347.76, divided into 6,117,388 common shares with a nominal value of CHF 0.02 each. Pursuant to the Merger, our shareholders received one common share with a nominal value of CHF 0.02 of Auris NewCo for every 10 common shares in Auris Medical Holding AG held prior to the Merger, effectively resulting in a "reverse share split" at a ratio of 10-for-1. Auris NewCo changed its name to "Auris Medical Holding AG" as part of the consummation of the Merger, effective March 13, 2018. On March 14, 2018 the common shares of Auris NewCo began trading on the Nasdaq Capital Market under the trading symbol "EARS." In a letter dated March 28, 2018, Nasdaq notified us that we had regained compliance with Listing Rule 5550(a)(2) and that the matter was now closed.

In addition to the minimum closing bid price requirement, we are required to comply with certain other Nasdaq continued listing requirements, including a series of financial tests relating to shareholder equity, market value of listed securities and number of market makers and shareholders. If we fail to maintain compliance with any of those requirements, our common shares could be delisted from Nasdaq's Capital Market. On January 11, 2018 we received a letter from Nasdaq indicating that we have been provided a period of 180 calendar days, or until July 10, 2018 to regain compliance with Nasdaq's market value of listed securities requirement.

LPC Purchase Agreement

On May 2, 2018 we entered into a purchase agreement (the "2018 Commitment Purchase Agreement") and a Registration Rights Agreement (the "2018 Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Pursuant to the Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces a purchase agreement we entered into with LPC on October 10, 2017 (the "2017 Commitment Purchase Agreement") which was terminated as a result of the Merger.

Offering of Common Shares and Warrants

On January 26, 2018, we entered into a Purchase Agreement with certain investors providing for the issuance and sale by us of 12,499,999 of our common shares. The common shares were offered pursuant to our effective shelf registration statement on Form F-3, which was initially filed with the Securities and Exchange Commission on September 1, 2015 and declared effective on September 10, 2015 (File No. 333-206710). We refer to such offering of common shares as the "January 2018 Registered Offering."

In a concurrent private placement, we sold to the investors in the January 2018 Registered Offering warrants to purchase one of our common shares for each common share purchased in the January 2018 Registered Offering. The warrants cover, in the aggregate, 7,499,999 of our common shares. The warrants became exercisable immediately upon their issuance on January 30, 2018 at an exercise price of $0.50 per common share, and expire on January 30, 2025. Following the consummation of the Merger, the warrants are exercisable for an aggregate of 750,002 of our common shares (assuming we round up fractional common shares to the next whole common share), at an exercise price of $5.00 per common share.

Amendment of Hercules Loan and Security Agreement

On April 5, 2018, we entered into an agreement with Hercules Capital, Inc. ("Hercules") whereby the terms of our Loan and Security Agreement (the "Loan and Security Agreement") with Hercules were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Loan and Security Agreement.

Collaboration and License Agreements

There have been no material changes to our collaboration and license agreements from those reported in "Item 5—Operating and Financial Review and Prospects–Operating results—Collaboration and License Agreements" in the Annual Report.

Research and Development Expense

Our research and development expense is highly dependent on the development phases of our research projects and therefore may fluctuate substantially from period to period. Our research and development expense mainly relates to the following key programs:

- *Keyzilen® (AM-101).* We conducted a Phase 3 clinical development program with Keyzilen® comprising two Phase 3 trials and two open label follow-on trials. We completed enrollment of the last of these trials (TACTT3) in September 2017. On March 13, 2018, we announced that preliminary top-line data from the TACTT3 trial indicated that the study did not meet its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Index score from baseline to Day 84 in the active treated group compared to placebo either in the overall population or in the otitis media subpopulation. We are currently investigating the outcomes, including those in TACTT2, the previously conducted sister trial. We anticipate that our research and development expenses in connection with the Keyzilen® trials will be lower in 2018 than in 2017, reflecting the completion of these trials.

- *AM-111*. We conducted a Phase 3 clinical development program with AM-111 comprising two Phase 3 trials in the treatment of ISSNHL, titled HEALOS and ASSENT. On November 28, 2017, we announced that the HEALOS trial did not meet the primary efficacy endpoint of a statistically significant improvement in hearing from baseline to Day 28 compared to placebo for either active treatment groups in the overall study population. However, a post-hoc analysis of the subpopulation with profound acute hearing loss revealed a clinically meaningful and nominally significant improvement in the AM-111 0.4 mg/mL treatment group. We terminated the ASSENT trial as it was very similar in design to the HEALOS trial and, based on the new findings, was no longer adequate for testing AM-111. We received feedback from the EMA regarding the design of a future Phase 3 trial and on the regulatory path forward and intend to seek in a next step regulatory feedback also from the FDA. We expect that our research and development expenses in connection with the AM-111 trials will be lower in 2018 than in 2017, reflecting the completion of these trials.

- *AM-125*. In the first quarter of 2018, we initiated a second Phase 1 trial in healthy volunteers to further test the safety and tolerability and the pharmacokinetics of AM-125. We expect to obtain the results of the study in summer 2018.

Other research and development expenses mainly relate to our pre-clinical studies of AM-102 (second generation tinnitus treatment). The expenses mainly consist of costs for synthesis of the pre-clinical compounds and costs paid to academic and other research institutions in conjunction with pre-clinical testing.

For a discussion of our other key financial statement line items, please see "Item 5—Operating and Financial Review and Prospects–Operating results—Financial Operations Overview" in the Annual Report.

Results of Operations

The numbers below have been derived from our unaudited condensed consolidated interim financial statements as of and for the three months ended March 31, 2018 and 2017. The discussion below should be read along with this financial information, and it is qualified in its entirety by reference to them.

Comparison of the three months ended March 31, 2018 and 2017

	Three months ended March 31		
	2018	2017	Change
	(in thousands of CHF)		%
Research and development	(2,943)	(5,981)	(51%)
General and administrative	(1,361)	(1,426)	(5%)
Operating loss	(4,304)	(7,407)	(42%)
Interest income	—	31	(100%)
Interest expense	(349)	(421)	(17%)
Foreign currency exchange loss, net	(88)	(338)	(74%)
Revaluation gain from derivative financial instruments	3,301	233	1,317%
Transaction costs	(314)	(506)	(38%)
Loss before tax	(1,754)	(8,408)	(79%)
Income tax gain	9	8	13%
Net loss attributable to owners of the Company	(1,745)	(8,400)	(79%)
Other comprehensive loss:			
Items that will never be reclassified to profit or loss			
Remeasurements of defined benefit liability	281	228	23%
Items that are or may be reclassified to profit and loss			
Foreign currency translation differences	15	20	(25%)
Other comprehensive gain	296	248	19%
Total comprehensive loss attributable to owners of the Company	(1,449)	(8,152)	(82%)

Research and development expense

	Three months ended March 31		
	2018	2017	Change
	(in thousands of CHF)		%
Clinical projects	(1,490)	(4,189)	(64%)
Pre-clinical projects	(213)	(142)	50%
Drug manufacturing and substance	(334)	(486)	(31%)
Employee benefits	(565)	(825)	(32%)
Other research and development expenses	(340)	(340)	0%
Total	(2,943)	(5,981)	(51%)

Research and development expenses amounted to CHF 2.9 million in the three months ended March 31, 2018. This represents a decrease of about CHF 3.0 million from research and development expenses of CHF 6.0 million for the three months ended March 31, 2017. Research and development expenses reflected the following:

- *Clinical projects.* In the three months ended March 31, 2018 clinical expenses were lower than in the three months ended March 31, 2017 by CHF 2.7 million. Lower service and milestone costs for our Keyzilen® and AM-111 studies, mainly reflecting the completion of TACTT2, AMPACT1 and AMPACT2 and progression towards completion of TACTT3, HEALOS and ASSENT trials.

- *Pre-clinical projects*. In the three months ended March 31, 2018, pre-clinical expenses increased by CHF 0.1 million compared to the three months ended March 31, 2017, primarily due to activities related to our AM-125 program.

- *Drug manufacture and substance.* In the three months ended March 31, 2018, drug manufacture and substance related costs decreased by CHF 0.1 million compared to the three months ended March 31, 2017, due to a temporary decrease in project activities.

- *Employee benefits*. Employee expenses decreased by CHF 0.3 million in the three months ended March 31, 2018 compared to the same period in 2017 primarily due to a reduction in headcount.

- *Other research and development expenses*. Other research and development expenses in the three months ended March 31, 2018 were in line with the corresponding period in 2017.

General and administrative expense

	Three months ended March 31,		
	2018	2017	Change
	(in thousands of CHF)		%
Employee benefits	(185)	(559)	(67%)
Lease expenses	(17)	(52)	(67%)
Business development	(10)	—	N.A.
Travel and representation	(10)	(80)	(88%)
Administration costs	(1,121)	(592)	89%
Depreciation tangible assets	(15)	(19)	(19%)
Capital tax expenses	(3)	(124)	(98%)
Total	(1,361)	(1,426)	(4%)

General and administrative expense amounted to CHF 1.4 million in the three months ended March 31, 2018 compared to CHF 1.4 million in the same period in the previous year. Administration cost were higher mainly due to higher legal fees related to the merger transaction. Lower employee benefits was mainly related to lower headcount and employee benefit-related expenses.

Interest income

Interest income decreased in the three months ended March 31, 2018 compared to the three months ended March 31, 2017, due to the termination of short-term deposits.

Interest expense

Interest expense was decreased in the three months ended March 31, 2018 compared to the same prior year period by CHF 0.1 million. The decrease relates to a reduction in the outstanding balance of the loan under the Hercules Loan and Security Agreement, as we commenced repayment of the loan facility in July 2017.

Foreign currency exchange gain / (loss), net

For the three months ended March 31, 2018, foreign currency exchange loss was CHF 0.3 million lower than during the same period in the previous year, primarily due to the appreciation of the US$ currency subsequent to January 30, 2018, when net proceeds of approximately $4.9 million were received in connection with the January 2018 Registered Offering.

Revaluation gain / (loss) from derivative financial instruments

In connection with the Hercules Loan and Security Agreement, we issued Hercules a warrant to purchase up to 241,117 of the Company's common shares at an exercise price of US$ 3.94 per share. As of March 13, 2018 following the consummation of the Merger, the warrant was exercisable for 15,673 common shares at an exercise price of $39.40 per common share. As of March 31, 2018 the fair value of the warrant amounted to CHF 4,596. The revaluation gain of the derivative for the three months ended March 31, 2018 amounted to CHF 18,754, which is a decrease of CHF 15,999 when comparing to the same period in 2017. Since its initial recognition, the fair value decreased by CHF 403,584, resulting in a revaluation gain in the corresponding amount (fair value as of July 19, 2016: CHF 408,180).

On February 21, 2017 we issued 10,000,000 warrants in connection with a public offering of 10,000,000 common shares, each warrant entitling its holder to purchase 0.70 of a common share at an exercise price of US$ 1.20. Additionally, the underwriter was granted a 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants, of which the underwriter partially exercised its option for 1,350,000 warrants. As of March 13, 2018, following the consummation of the Merger, the warrants became exercisable for an aggregate of 794,000 of our common shares, at an exercise price of $12.00 per common share. As of March 31, 2018, the fair value of the warrants amounted to CHF 300,011. The revaluation gain of the derivative for the three months ended March 31, 2018 amounted to CHF 1,513,402, which is an increase of CHF 1,291,682 when comparing to the same period in 2017. Since its initial recognition, the fair value decreased by CHF 4,790,452, resulting in a gain in the corresponding amount (fair value as of February 21, 2017: CHF 5,090,463).

On January 30, 2018 we issued 7,499,999 warrants in connection with a direct offering of 12,499,999 common shares, each warrant entitling its holder to purchase one common share at an exercise price of $0.50. As of March 13, 2018, following the consummation of the Merger, the warrants became exercisable for an aggregate of 750,002 of our common shares (assuming we decide to round up fractional common shares to the next whole common share), at an exercise price of $5.00 per common share. As of March 31, 2018 the fair value of the warrants amounted CHF 715,206. Since its initial recognition, the fair value of the warrants has decreased by CHF 1,768,541, resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).

Transaction costs

Transaction costs decreased by CHF 0.2 million in the three months ended March 31, 2018 compared to the previous period, due to lower fees and transaction costs related to the equity offering in the first quarter of 2018 compared to the equity offering in the first quarter of 2017.

Cash flows

Comparison of the three months ended March 31, 2018 and 2017

The table below summarizes our cash flows for the three months ended March 31, 2018 and 2017:

	Three months ended	
	2018	2017
	(in thousands of CHF)	
Cash used in operating activities	(4,981)	(6,775)
Net cash used in investing activities	—	(44)
Net cash from financing activities	2,963	8,787
Net effect of currency translation on cash	(302)	(563)
Cash and cash equivalents at beginning of the period	14,973	32,442
Cash and cash equivalents at end of the period	12,654	33,847

The decrease in net cash used in operating activities from CHF 6.8 million in the three months ended March 31, 2017 to CHF 5.0 million in the three months ended March 31, 2018 was mainly due to lower operating expenses compared to the same period in 2017.

Cash and funding sources

On May 2, 2018 we entered into the 2018 Commitment Purchase Agreement and the 2018 Registration Rights Agreement with Lincoln Park Capital Fund, LLC ("LPC"). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces the 2017 Commitment Purchase Agreement, which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares and prior to its termination, we had issued an aggregate of 2,600,000 common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement.

On January 30, 2018 we completed a public offering of 12,499,999 common shares with a nominal value of CHF 0.40 each and a concurrent offering of 7,499,999 warrants, each warrant entitling its holder to purchase one common share. The net proceeds to the Company from the January 2018 Registered Offering were approximately $4.9 million, after deducting placement agent fees and other estimated offering expenses payable by the Company. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issued in the January 2018 offering were exercisable for up to 750,002 common shares (assuming we decide to round up fractional common shares to the next whole common share) at an exercise price of $5.00 per common share.

On October 16, 2017 we issued 1,744,186 common shares to LPC for aggregate proceeds of $1,500,000.

On February 21, 2017 we completed a public offering of 10,000,000 common shares with a nominal value of CHF 0.40 each and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The net proceeds to us from the offering were approximately CHF 9.1 million, after deducting underwriting discounts and other offering expenses payable by us. The underwriter was granted a 30-day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants, of which the underwriter partially exercised its option in the amount of 1,350,000 warrants. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issued in the February 2017 offering were exercisable for up to 794,500 common shares at an exercise price of $12.00 per common share.

On July 19, 2016 the Company entered into the Loan and Security Agreement with Hercules for a secured term loan facility of up to $20.0 million. An initial tranche of $12.5 million was drawn on July 19, 2016, concurrently with the execution of the loan agreement. The loan matures on January 2, 2020 and bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. The loan is secured by a pledge of the shares of Auris Medical AG owned by the Company, all intercompany receivables owed to the Company by its Swiss subsidiaries and a security assignment of the Company's bank accounts. In connection with the loan facility, we issued Hercules a warrant to purchase up to 241,117 of our common shares at an exercise price of $3.94 per share. As of March 13, 2018, following consummation of the Merger, the warrant is exercisable for 15,673 common shares at an exercise price of $39.40 per common share. On April 5, 2018 we entered into an agreement with Hercules whereby the terms of the Company's Loan and Security Agreement with Hercules were amended to eliminate the $5 million liquidity covenant in exchange for a repayment of $5 million principal amount outstanding under the Loan and Security Agreement.

We have no other ongoing material financial commitments, such as lines of credit or guarantees that are expected to affect our liquidity over the next five years, other than leases.

Funding requirements

We expect that our operating expenses for 2018 will be in the range of CHF 10.0 to CHF 12.0 million and that the existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2018. In addition, we anticipate that the issuance of our common shares under the LPC Purchase Agreement will enable the Company to further fund its operations and capital requirements. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:

- the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities;
- the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;
- the number and characteristics of product candidates that we pursue;
- the cost, timing, and outcomes of regulatory approvals;
- the cost and timing of establishing sales, marketing, and distribution capabilities; and
- the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder.

We expect that we will require additional funding to continue our ongoing clinical development activities and seek to obtain regulatory approval for, and commercialize, our product candidates. If we receive regulatory approval for any of our product candidates, and if we choose not to grant any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. Likewise, if we are unable to refinance amounts outstanding under our existing term loan facility before such amounts are due we may be unable to repay such amounts, which could result in foreclosure of the collateral pledged to secure such loan.

We may raise additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares. We may also seek to refinance out outstanding indebtedness.

For more information as to the risks associated with our future funding needs, see “Item 3—Key Information—Risk factors” in the Annual Report.

Contractual Obligations and Commitments

The following table presents information relating to our contractual obligations as of March 31, 2018:

	Payments Due by Period			
	Less Than 1 Year	Between 1 and 3 Years	Between 3 and 5 Years	Total
	(in thousands of CHF)			
Operating lease obligations (1)	161	298	75	534
Long-term debt obligations (2)	4,590	4,931	—	9,521
Derivative Financial Instruments (3)	—	—	1,020	1,020
Total	4,751	5,229	1,095	11,075

(1) Operating lease obligations consist of payments pursuant to non-cancellable operating lease agreements relating to leases of our office space and are not accounted for on the balance sheet. The lease term is 5 years. The lease expires on September 30, 2021 with an option to extend for another five years.

(2) Long-term debt obligations consist of amortization payments and the end of term fee due under the Hercules Loan and Security Agreement converted to CHF at an exchange rate of CHF 0.9584 to US$1.00. The secured term loan under the Hercules Loan and Security Agreement has a maturity date of January 2, 2020, with an interest-only period through July 1, 2017, and amortized payments of principal and interest thereafter in equal monthly instalments until the maturity date. The loan bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. Interest payments are not included in the table presented above.

(3) Derivative Financial instruments relate to the warrants issued in connection with the Hercules Loan and Security Agreement and the warrants issued in the public offering in February 2017 and direct placement in January 2018.

Under the terms of our collaboration and license agreement with Xigen, we are obliged to make development milestone payments on an indication-by-indication basis of up to CHF 1.5 million upon the successful completion of a Phase 2 clinical trial and regulatory milestone payments on a product-by-product basis of up to CHF 2.5 million, subject to a mid-twenties percentage reduction for smaller indications, e.g., those qualifying for orphan drug status, upon receiving marketing approval for a product. The milestones are not included in the table above as they have not met the recognition criteria for provisions and the timing of these is not yet determinable as it is dependent upon the achievement of earlier mentioned milestones.

Under the terms of the asset purchase agreement with Otifex Therapeutics Pty Ltd, we are obliged to make a development milestone payment of $200,000 if use of the purchased formulation is supported by the results from toxicology studies over three to six months.

Off-Balance Sheet Arrangements

As of the date of this discussion and analysis, we do not have any, and during the periods presented we did not have any, off-balance sheet arrangements except for the Operating Lease mentioned in “Item 5—Operating and Financial Review and Prospects—Tabular disclosure of contractual obligations” in the Annual Report.

Significant Accounting Policies and Use of Estimates and Judgment

There have been no material changes to the significant accounting policies and estimates described in "Item 5—Operating and Financial Review and Prospects–Operating results—Significant accounting policies and use of estimates and judgment" in the Annual Report.

Recent Accounting Pronouncements

There are no IFRS standards as issued by the IASB or interpretations issued by the IFRS interpretations committee that are effective for the first time for the financial year beginning on or after January 1, 2018 that would be expected to have a material impact on our financial position.

JOBS Act Exemption

On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company". As an emerging growth company, we are not required to provide an auditor attestation report on our system of internal controls over financial reporting. This exemption will apply for a period of five years following the completion of our initial public offering (2019) or until we no longer meet the requirements of being an "emerging growth company," whichever is earlier. We would cease to be an emerging growth company if we have more than US$1.0 billion in annual revenue, have more than US$700 million in market value of our common shares held by non-affiliates or issue more than US$1.0 billion of non-convertible debt over a three-year period.

Cautionary Statement Regarding Forward Looking Statements

Forward-looking statements appear in a number of places in this discussion and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to:

- our operation as a development-stage company with limited operating history and a history of operating losses;
- our need for substantial additional funding to continue the development of our product candidates before we can expect to become profitable from sales of our products;
- the outcome of our review of strategic options and of any action that we may pursue as a result of such review;
- our dependence on the success of Keyzilen® (AM-101), AM-111 and AM-125, which are still in clinical development and may eventually prove to be unsuccessful, or that the post-hoc analysis in the subpopulation of profound acute hearing loss patients in the HEALOS trial may not be considered acceptable for regulatory filing purposes by relevant health authorities, which may impair our ability to raise additional funding to continue the development of our product candidates;
- the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates in the clinic or in the commercial stage;
- the chance our clinical trials may not be completed on schedule, or at all, as a result of factors such as delayed enrollment or the identification of adverse effects;
- uncertainty surrounding whether any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized;
- if our product candidates obtain regulatory approval, our being subject to expensive, ongoing obligations and continued regulatory overview;
- enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;
- the chance that we do not obtain orphan drug exclusivity for AM-111, which would allow our competitors to sell products that treat the same conditions;
- dependence on governmental authorities and health insurers establishing adequate reimbursement levels and pricing policies;
- our products may not gain market acceptance, in which case we may not be able to generate product revenues;
- our reliance on our current strategic relationships with INSERM or Xigen and the potential success or failure of strategic relationships, joint ventures or mergers and acquisitions transactions;
- our reliance on third parties to conduct our nonclinical and clinical trials and on third-party, single-source suppliers to supply or produce our product candidates;
- our ability to obtain, maintain and protect our intellectual property rights and operate our business without infringing or otherwise violating the intellectual property rights of others;
- our ability to comply with the requirements under our term loan facility with Hercules, including repayment of amounts outstanding when due;
- our ability to meet the continuing listing requirements of Nasdaq and remain listed on the Nasdaq Capital Market;
- the chance that certain intangible assets related to our product candidates will be impaired; and

- other risk factors set forth in our most recent Annual Report on Form 20-F.

Our actual results or performance could differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations, cash flows or financial condition. Except as required by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results

Ÿ *Expansion of intranasal betahistine program into mental health supportive care*

Ÿ *Initiating project AM-201 for the treatment of histaminergic receptor mediated weight gain and drowsiness in patients treated with antipsychotic medications*

Ÿ *Positive scientific advice from EMA on development plan and regulatory pathway for AM-111*

Zug, Switzerland, May 15, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today provided a business and strategy update and announced financial results for the first quarter ended March 31, 2018. As part of the strategy update, the Company announced the expansion of its intranasal betahistine AM-125 development program beyond the treatment of vertigo into mental health supportive care indications. Under project code AM-201 the Company will develop intranasal betahistine for the treatment of histaminergic receptor mediated weight gain and drowsiness (somnolence), which are major side effects of many antipsychotic drugs.

“Obesity and related metabolic disorders are major issues in the treatment of mental illnesses like schizophrenia or bipolar disorder, arising largely as adverse side effects from the use of antipsychotic drugs”, commented John W. Newcomer, MD, Professor of Integrated Medical Science at the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. “Increased rates of diabetes, dyslipidemia, and cardiovascular disease observed in this patient population are known complications of antipsychotic treatment, particularly with those medications that produce the largest adverse effects on body weight. Histamine plays a key role in the brain’s regulation of food intake and energy expenditure, and antipsychotic drugs with higher risk for weight gain block histamine H_1 receptors – therefore, histamine receptors have become a promising target for modifying antipsychotic-induced weight gain and metabolic risk, with accumulating preclinical and clinical evidence to support this approach.”

“We are very excited to launch the development of intranasal betahistine for mental health supportive care indications“, stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “For decades betahistine has been a cornerstone treatment for vertigo in many countries around the world, but its clinical utility has been limited due to the poor bioavailability associated with the oral administration route. Previous clinical research with oral betahistine, which acts as an H_1 receptor agonist, also suggested therapeutic benefits in the treatment of antipsychotic induced weight gain. With intranasal delivery we can significantly improve betahistine’s bioavailability, which we expect to translate into enhanced treatment outcomes in both indications. We believe that the AM-201 program will be highly synergistic to the AM-125 program and represents a natural extension into an attractive therapeutic area.” Auris Medical plans to provide further details on the AM-201 program through a KOL call in early June 2018.

As the Company focuses on advancing its AM-125 and AM-201 programs with intranasal betahistine, it plans to move forward with its late-stage programs AM-111 for the treatment of acute inner ear hearing loss and AM-101 for the treatment of acute inner ear tinnitus through strategic partnering and with non-dilutive funding. In line with this strategy, the Company is reducing the level of operating expenses, which we believe will result in a further and marked reduction of the cash burn rate.

Development Program Updates

AM-125 for Vertigo

Ÿ Completed oral dosing arm of second Phase 1 clinical trial in healthy volunteers. The first part of the study with administration of escalating doses of oral betahistine up to 384 mg has been completed. Pharmacokinetic data from this part are expected to provide further support for bridging to existing safety data with oral betahistine. In the second part of the study intranasal betahistine will be administered to determine the maximum tolerated dose with single and repeated dosing and generate additional data on bioavailability in humans. An earlier single dose Phase 1 clinical trial with intranasal betahistine up to 40 mg had shown a relative bioavailability which was 20-40 times higher compared with plasma levels in an independent Phase 1

clinical trial with oral betahistine at 3 x 48 mg/day.[1] Results from the second Phase 1 trial are expected to become available in the third quarter of 2018.

- Initiated preparations for Phase 2 clinical trial in vertigo. The Company is planning to start a randomized controlled Phase 2 trial in patients suffering from acute surgery-induced vertigo towards the end of 2018. The preparations will include, among others, discussions with health authorities for validation of the study design, additional toxicology testing, as well as further pharmaceutical development work.

- Expanded patent estate related to betahistine. The Company acquired two US patents related to the use of betahistine for treating weight gain induced by the antipsychotic drug olanzapine – US patent 7,728,015 “Compositions for weight management” and US patent 7,737,165 "Methods of reducing weight gain associated with olanzapine treatment".

AM-111 for Acute Inner Ear Hearing Loss

- Reported the publication of a peer-reviewed review article entitled "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" in Hearing Research, one of the leading journals in the otorhinolaryngology field. The publication reviews AM-111’s mechanism of action, pharmacokinetics and therapeutic applications.

- Received positive Scientific Advice (Protocol Assistance) from the European Medicines Agency (EMA) related to the development plan and regulatory pathway for AM-111. The Scientific Advice had been requested by the Company following the results of the HEALOS Phase 3 trial. The Agency endorsed the proposed design for a single pivotal trial with AM-111 0.4 mg/mL in patients suffering from acute profound hearing loss design, the choice of efficacy and safety endpoints, as well as the statistical methodology. In addition, the EMA provided important guidance on the regulatory path forward and the maintenance of AM-111's orphan drug designation.

- Preparing for FDA consultation. The Company plans to request a Type C meeting with the FDA to discuss the development and regulatory path forward.

Keyzilen® (AM-101) for Acute Inner Ear Tinnitus

- Conducted in-depth analyses of full outcomes from the TACTT3 trial. On March 13, 2018 the Company reported that the study did not meet its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Index score from baseline to Day 84 in the active treated group compared to placebo either in the overall population or in the otitis media subpopulation. Further investigation of the trial’s outcomes confirmed these preliminary results. The Company believes that the lack of separation between the active- and placebo-treated groups may be due to certain elements of the study design and conduct.

- Evaluating next steps with AM-101. Given the strong unmet medical need and in view of the positive data from non-clinical studies, two Phase 2 trials and the two open label AMPACT trials, the Company is assessing measures to address the issues arising in both TACTT trials and how best to advance the program.

Corporate Developments

- Regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market following a “reverse share split” at a ratio of 10-for-1 of the Company’s common shares effectuated through the consummation of the merger with a wholly-owned subsidiary, effective March 13, 2018. At the end of the first quarter 2018 the Company had a total of 6,117,388 common shares outstanding.

[1] The overall design of that trial is described in Barak et al. (2016), Journal of Psychopharmacology 30(3): 237-241.

- Renewed the equity line with Lincoln Park Capital, LLC (LPC). On May 2, 2018, the Company entered into a new equity line for up to $10 million with LPC. The previous equity line with LPC had been terminated upon the Company's merger with one of its subsidiaries in order to effect the reverse share split.

- Made an early repayment in April 2018 of $5 million principal amount outstanding under a loan and security agreement with Hercules Capital, Inc. In return, the agreement was amended to remove the liquidity covenant of $5 million. The repayment will reduce the Company's annual interest expense by more than $0.5 million.

First Quarter 2018 Financial Results

- Cash and cash equivalents at March 31, 2018 totaled CHF 12.7 million. In January 2018 the Company effected a direct registered offering of 12.5 million common shares at a price of $0.44 per share,[2] which resulted in net proceeds of CHF 4.6 million.

- Total operating expenses for the first quarter of 2018 were CHF 4.3 million compared to CHF 7.4 million for the first quarter of 2017.

- Research and development expenses for the first quarter of 2018 were CHF 2.9 million compared to CHF 6.0 million for the first quarter of 2017.

- General and administrative expenses for the first quarter of 2017 were CHF 1.4 million compared to CHF 1.4 million for the first quarter of 2017.

- Net loss for the first quarter of 2018 was CHF 1.7 million, or CHF 0.30 per share, compared to CHF 8.4 million, or CHF 2.15 per share, for the first quarter of 2017.[3]

The Company continues to expect that its operating expenses in 2018 will be in the range of CHF 10 to 12 million.

Conference Call & Webcast Information

Auris Medical will host a conference call and webcast to present the first quarter 2018 financial results and to provide a business and strategy update today, May 15, 2018, at 8:00 am Eastern Time (2:00 pm Central European Time). To participate in this conference call, dial 1-866-575-6539 (USA) or +1-323-794-2575 (International), and enter passcode 8957322. A live webcast of the conference call will be available in the Investor Relations section of the Auris Medical website at www.aurismedical.com and a replay of the conference call will be available following the live call.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1. In addition Auris Medical has two Phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol "EARS."

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should",

[2] 1.25 million shares at a price of $4.40 per share adjusted for subsequent reverse stock split.

[3] Loss per share for first quarter 2017 adjusted for subsequent reverse stock split.

“expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the ability to pursue strategic partnering and non-dilutive funding for its Phase 3 programs, the results of Auris Medical’s review of strategic options and the outcome of any action taken as a result of such review, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2017, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Company contact: Hernan Levett, Chief Financial Officer, +41 61 201 1350
investors@aurismedical.com

AURIS MEDICAL HOLDING AG
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss
For the Three Months Ended March 31, 2018 and 2017 (in CHF)

	THREE MONTHS ENDED MARCH 31	
	2018	**2017**
Research and development	(2,943,221)	(5,981,419)
General and administrative	(1,360,714)	(1,425,491)
Operating loss	**(4,303,935)**	**(7,406,910)**
Interest income	—	31,297
Interest expense	(348,927)	(421,435)
Foreign currency exchange loss, net	(88,290)	(338,160)
Revaluation gain from derivative financial instruments	3,300,696	233,123
Transaction costs	(313,760)	(506,234)
Loss before tax	**(1,754,216)**	**(8,408,319)**
Income tax gain	8,726	8,191
Net loss attributable to owners of the Company	**(1,745,490)**	**(8,400,128)**
Other comprehensive loss:		
Items that will never be reclassified to profit or loss		
Remeasurement of defined benefit liability, net of taxes of CHF 0.00	280,801	227,827
Items that are or may be reclassified to profit or loss		
Foreign currency translation differences, net of taxes of CHF 0.00	15,135	19,925
Other comprehensive income, net of taxes of CHF 0	**295,936**	**247,752**
Total comprehensive loss attributable to owners of the Company	**(1,449,554)**	**(8,152,376)**
Basic and diluted loss per share	(0.30)	(2.15)
Average weighted number of shares outstanding, adjusted for effect of reverse stock split	5,742,978	3,904,881

AURIS MEDICAL HOLDING AG
Condensed Consolidated Statement of Financial Position
(in CHF)

	MARCH 31, 2018	DECEMBER 31, 2017
ASSETS		
Non-current assets		
Property and equipment	229,450	252,899
Intangible assets	1,629,100	1,629,100
Other non-current financial receivables	76,710	76,710
Total non-current assets	**1,935,260**	**1,958,709**
Current assets		
Other receivables	370,001	241,281
Prepayments	832,033	652,913
Cash and cash equivalents	12,653,690	14,973,369
Total current assets	**13,855,724**	**15,867,563**
Total assets	**15,790,984**	**17,826,272**
EQUITY AND LIABILITIES		
Equity		
Share capital	122,348	19,349,556
Share premium	136,332,888	114,648,228
Foreign currency translation reserve	(17,912)	(33,047)
Accumulated deficit	(137,850,994)	(136,126,946)
Total shareholders (deficit)/equity attributable to owners of the Company	**(1,413,670)**	**(2,162,209)**
Non-current liabilities		
Loan	4,414,950	5,584,297
Derivative financial instruments	1,019,813	1,836,763
Employee benefits	1,734,689	1,962,970
Deferred tax liabilities	170,083	178,809
Total non-current liabilities	**7,339,535**	**9,562,839**
Current liabilities		
Loan	4,226,770	4,542,109
Trade and other payables	1,355,721	1,200,820
Accrued expenses	4,282,628	4,682,713
Total current liabilities	**9,865,119**	**10,425,642**
Total liabilities	**17,204,654**	**19,988,481**
Total equity and liabilities	**15,790,984**	**17,826,272**